Our Research Results

Since we first began more than 40 years ago, Breast Cancer Trials (BCT) has contributed to more than 1,200 peer-reviewed publications and many of these research results have changed practice in the treatment and prevention of breast cancer.

The publication of the results of clinical trials research in a scientific journal or a periodic publication:

  • Fulfils the researchers’ ethical obligations to research participants and the general community;
  • Contributes to medical knowledge so doctors can make scientifically valid assessments of the benefits and risks of a new medicine or treatment for their patients.

BCT publishes study results in accordance with the BCT Publication Policy.

The citations for all of these publications are listed below, ordered by year. To search for a citation, enter a keyword/s and click search. Enclose multiple words in quotes “” to search for an exact match. Alternatively, you can search for clinical trials in a given year or for a particular clinical trial name. 

The majority of the publications can be accessed via PubMed, other research databases or publication storage systems at a university library (if you are a student/member), or directly to the journal or publication online. Many scientific journals provide articles as “open access”; however some require a subscription.

PUBLICATIONS

2024

Multiplexed high-thoroughput immune cell imaging in patients with high-risk triple negative early breast cancer: Analysis from the International Breast Cancer Study Group (IBCSG) Trial 22-00.

Rusakiewicz S, Tyekucheva S, Tissot-Renaud S, Chaba K, Imbimbo M, Benedetti F, Kammler R, Hornfeld J, Munzone E, Gianni L, Thuerlimann B, Pruneri G, Gray K, Lang I, Regan MR, Loi S, Colleoni M, Viale G, Kandalaft L, Coukos G, Curigliano G. European Journal of Cancer. 2024; 200113535, doi: 10.1016/j.ejca.2024.113535. Epub 2024 Jan 24., E-pub

Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer.

Ganz PA, Bandos H, Spanic T, Friedman S, Muller V, Kuemmel S, Delaloge S, Brain E, Toi M, Yamauchi H, de Duenas E-M, Armstrong A, Im S-A, Song C, Zheng H, Sarsiek T, Sharma P, Geng C, Fu P, Rhiem K, Frachiger-Heuer H, Wimberger P, d’Kind de Roodenbeke D, Liao N, Goodwin A, Chakiba-Brugere C, Friedlander M, Lee KS, Giacchetti S, Takano T, Henao-Carrasco F, Virani S, Valdes-Albini F, Domchek SM, Bane C, McCarron EC, Mita M, Rossi G, Rastogi P, Fielding A, Gelber RD, et al. Journal of Clinical Oncology. 2024; 42(11):1288-1300, DOI https://doi.org/10.1200/JCO.23.01214, E-pub

Quality of life outcomes associated with optimization of treatment by omitting radiotherapy in early breast cancer.

Stafford L, Sinclair M, Butow P, Hughes J, Park A, Gilham L, Rose A, Mann GB. Clinical Breast Cancer. 2024; 1-10, ttps://doi.org/10.1016/j.clbc.2024.03.002, E-pub

What About This IDEA: The PROSPECT That Occult Malignant Lesions May Explain Local Recurrences in Very Early Breast Cancer?

Mann G.B., Rose A.K., Zdenkowski N. Journal of Clinical Oncology. 2024; JCO.23.02729 DOI:10.1200/JCO.23.02729epub 15 March 2024, Correspondence

Overall survival with palbociclib plus letrozole in advanced breast cancer.

Slamon DJ, Diera V, Rugo HS, Harbeck N, Im S-A, Gelmon KA, Lipatov ON, Walshe JM, Martin M, Chavez-MacGregor M, Bananis E, Gauthier E, Lu DR, Kim S, Finn RS. Journal of Clinical Oncology. 2024; 42(9):994-1000, DOI https://doi.org/10.1200/JCO.23.00137, E-pub

2023

Current bi-national attitudes towards targeted axillary dissection. [BCT Clinical Fellowship].

Ofri A, Spillane AJ, Baker C, Mann GB, Walker M, Warrier S. ANZ Journal of Surgery. 2023; https://doi.org/10.1111/ans.18841, E-pub

Total Publications: 1310